# IDeate-Prostate01 (NCT06925737)

> A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06925737
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Prostate Cancer; Prostatic Neoplasms
- Interventions: Ifinatamab deruxtecan; Docetaxel; Prednisone; Rescue Medication
- Enrollment: 1440
- Primary outcome: Overall Survival (OS)
- Primary outcome: Radiographic Progression Free Survival (rPFS)

## Indexed commentary on IDeate-Prostate01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ideate-prostate01-nct06925737